Alkaline Phosphatase (ALP)

One note on units, since it spares a common worry. ALP is reported in U/L, and you may see IU/L on a report; on this test they mean the same thing, so a 110 in either label is the same result. There is only one set of numbers in routine use, so the unit confusion that trips up vitamin D readers does not arise here. The trap with ALP is not the unit. It is whose range you are reading it against.

The reference band on most reports is built for the average adult, and against it a healthy child or pregnant person can look abnormal. That is a reading error, not a finding.

MedlinePlus states it directly: children and teens may have high levels of ALP because their bones are growing. Cleveland Clinic puts the same point in terms of timing, noting ALP is typically elevated through childhood and puberty as bones develop. A child in active growth, and especially a teenager in a growth spurt, can run two to three times a typical adult level while being entirely well. Bone that is laying down new mineral is the loudest broadcaster of ALP there is, and a young skeleton broadcasts almost constantly. Pediatric results are read against age-specific ranges for exactly this reason; held up to the adult band, normal growth reads as a red flag.

Pregnancy carries its own built-in rise. The placenta makes its own form of alkaline phosphatase, so ALP climbs in the later months as ordinary physiology. MedlinePlus lists pregnancy among the causes of a higher-than-normal result, and Cleveland Clinic traces it to the placental source. A raised ALP in an otherwise healthy pregnancy is usually a third station joining the broadcast, not a sign the liver is in trouble. In both cases the lesson is the same: an "elevated" flag means little until you know who is doing the elevating.

Once a high ALP needs explaining in an adult, the job is to identify the source, and ALP alone cannot do it. This is where a second receiver comes in, one tuned to only one of the stations.

That receiver is GGT. Gamma-glutamyl transferase sits in the liver and bile ducts but is absent from bone, so it picks up the liver station and ignores the bone one entirely. MedlinePlus and StatPearls both describe the logic a clinician uses: when ALP and GGT are both raised, the source is the liver or bile ducts; when ALP is high but GGT reads normal, the trail leads toward a bone disorder instead. GGT does not make the diagnosis. It tells you which channel to listen to, and that one distinction is the most common reason a GGT is added after an ALP comes back high. The ALP versus GGT comparison walks through how the pair is read together.

There is also a more precise tuner. Cleveland Clinic describes an ALP isoenzyme test, a follow-up that can distinguish the chemical forms of ALP by where they originated, because liver damage and bone disorders produce genuinely different versions of the enzyme. It is more technically demanding and not every lab offers it, so in practice the GGT pairing does most of the everyday sorting and the isoenzyme test is reserved for when the source still is not clear. When alkaline phosphatase is high, the next question is whether the source is liver or bone, and a liver-specific enzyme such as 5'-nucleotidase is one way labs settle it.

The causes split along the two broadcasts. On the liver-and-bile side, what pushes ALP up most is a problem with bile flow rather than raw cell injury: a gallstone, an inflamed or narrowed bile duct, or anything that slows drainage. ALP and GGT rise together here, and a bile backup can eventually raise bilirubin too. The enzymes that flag liver-cell injury directly, ALT and AST, tend to move first when the problem is the cells themselves rather than the plumbing.

On the bone side, ALP rises wherever bone is being built or rebuilt at speed. MedlinePlus and Cleveland Clinic name the usual suspects: Paget's disease of bone, in which bone breaks down and regrows abnormally; osteomalacia, a softening of bone often tied to low vitamin D; a healing fracture, which lifts ALP as new bone forms; and, less commonly, cancers that have spread to bone. A specific bone fraction, bone-specific ALP, can be measured when the question is squarely skeletal, where it joins the formation markers on a bone health panel. And when the question is whether a known prostate cancer has reached bone, a rising ALP is read alongside PSA. A low ALP, by contrast, has little to say on its own and rarely draws a comment.

ALP reads best inside the group it was ordered with. The liver panel sets it beside GGT, the transaminases, and bilirubin, so the panel together can separate a bile-flow problem from cell injury from a backup of pigment. When a high ALP turns out to be skeletal, the conversation shifts toward bone, and markers like vitamin D and the bone-specific fraction carry it instead. No single enzyme names a cause; ALP marks that one of two systems is busy, and the company it keeps says which.

Because ALP moves with whatever is driving it in a given stretch, a single reading is a snapshot. An ALP of 160 means one thing in a 14-year-old, another in a pregnant woman in her third trimester, and another again in a 50-year-old whose GGT is climbing beside it. The first step is often just recognizing the line, since "ALP" is one of the enzyme codes a report prints without spelling out.